Table 3 Adjusted treatment differences and odds ratios at week 30

Change from baseline in DAS28-CRP score (95% CI)

Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA

− 0.107 (− 0.309; 0.095), p = 0.3012

− 0.587 (− 0.834; − 0.34), p < 0.0001

− 0.693 (− 0.993; − 0.393), p < 0.0001

− 0.578 (− 0.831; − 0.325), p < 0.0001

Change from baseline in CDAI score (95% CI)

Race, baseline CDAI, anti-CPP, HAQ-DI, PADA

− 1.138 (− 2.912; 0.636), p = 0.2087

− 3.551 (− 5.742; − 1.36), p = 0.0016

− 4.690 (− 7.438; − 1.942), p = 0.0009

− 3.502 (− 5.715; − 1.289), p = 0.002

Change from baseline in SDAI score (95% CI)

Race, baseline SDAI, anti-CPP, HAQ-DI, PADA

− 1.109 (− 2.983; 0.765), p = 0.2462

− 4.079 (− 6.411; − 1.747), p = 0.0006

− 5.188 (− 8.104; − 2.272), p = 0.0005

− 4.031 (− 6.385; − 1.677), p = 0.0008

Proportion of patients achieving a EULAR good response (CRP criteria)

Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA

1.293 (0.913; 1.831), p = 0.1482

2.066 (1.389; 3.071), p = 0.0004

2.671 (1.722; 4.142), p < 0.0001

2.268 (1.556; 3.305), p < 0.0001

Proportion of patients achieving ACR20 response

Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental

1.129 (0.806; 1.584), p = 0.4803

1.442 (0.765; 2.716), p = 0.2580

1.628 (0.797; 3.329), p = 0.1818

1.439 (0.763; 2.712), p = 0.261

Proportion of patients achieving ACR50 response

Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental

1.133 (0.802; 1.601), p = 0.4777

1.601 (1.019; 2.514), p = 0.0414

1.814 (1.033; 3.185), p = 0.0384

1.597 (1.016; 2.51), p = 0.0429

Proportion of patients achieving ACR70 response

Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental

1.256 (0.804; 1.965), p = 0.3171

1.731 (1.087; 2.758), p = 0.0211

2.176 (1.154; 4.102), p = 0.0165

1.72 (1.078; 2.746), p = 0.0231

Proportion of patients achieving DAS-28-CRP low disease activity: DAS28-CRP ≤ 3.2

Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA

1.248 (0.88; 1.771), p = 0.2137

2.097 (1.406; 3.127), p = 0.0003

2.618 (1.684; 4.07), p < 0.0001

2.273 (1.556; 3.322), p < 0.0001

Proportions of patients with DAS28-CRP remission: DAS28-CRP < 2.6

Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA

1.218 (0.822; 1.806), p = 0.3258

2.308 (1.509; 3.531), p = 0.0001

2.812 (1.747; 4.528), p < 0.0001

2.481 (1.660; 3.707), p < 0.0001

Proportion of patients achieving CDAI low disease activity: CDAI ≤ 10.0

Race, CDAI initial, anti-CPP, HAQ-DI, PADA

1.447 (1.029; 2.035), p = 0.0341

2.11 (1.427; 3.120), p = 0.0002

3.053 (1.980; 4.708), p < 0.0001

2.030 (1.312; 3.142), p = 0.0015

Proportions of patients achieving CDAI remission: CDAI ≤ 2.8

Race, CDAI initial, anti-CPP, HAQ-DI, PADA

1.291 (0.699; 2.384), p = 0.4145

1.224 (0.662; 2.263), p = 0.52

1.58 (0.679; 3.678), p = 0.2891

1.213 (0.654; 2.25), p = 0.5412

Proportion of patients achieving SDAI low disease activity: SDAI ≤ 11.0

Race, SDAI initial, anti-CPP, HAQ-DI, PADA

1.384 (0.985; 1.944), p = 0.0616

2.066 (1.392; 3.066), p = 0.0003

2.859 (1.850; 4.418), p < 0.0001

2.111 (1.383; 3.223), p = 0.0006

Proportions of patients achieving SDAI remission: SDAI ≤ 3.3

Race, SDAI initial, anti-CPP, HAQ-DI, PADA

1.337 (0.729; 2.454), p = 0.3487

1.23 (0.677; 2.233), p = 0.4967

1.644 (0.716; 3.779), p = 0.2417

1.219 (0.669; 2.219), p = 0.5179

Proportions of patients with Boolean remission

PADA, CRP, age, BMI

1.824 (0.54; 6.165), p = 0.3337

2.552 (0.926; 7.034), p = 0.0704

4.655 (1.105; 19.622), p = 0.0364

2.422 (0.846; 6.938), p = 0.0997

Proportion of patients achieving HAQ MCID improvement

HAQ-DI, age, SF-36 mental

1.505 (1.026; 2.208), p = 0.0370

1.549 (0.933; 2.57), p = 0.0908

2.331 (1.307; 4.158), p = 0.0043

1.67 (1.065; 2.619), p = 0.0258